Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
View Patent ↗The instant specification provides methods of treatment for inflammatory and autoimmune disorders of the metabolic system. The instant specification also provides methods of diagnosis.
1. A method of treating an individual predisposed to develop insulin-dependent diabetes mellitus (IDDM) comprising administering an effective amount of:
a) an anti-IL-23p19 antagonist antibody, or an antigen binding fragment thereof, or an anti-IL-23R antagonist antibody, or an antigen binding fragment thereof; and
b) an anti-IL-17 antagonist antibody, or an antigen binding fragment thereof.
2. The method of claim 1 , wherein at least one of the anti-IL-23p19 or anti-IL-23R antibodies, or antigen binding fragments thereof, or the anti-IL-17 antibody, or antigen binding fragment thereof, is a monoclonal antibody, or antigen binding fragment thereof.
3. The method of claim 1 , further comprising administering an immunosuppressive agent.
4. The method of claim 3 , wherein the immunosuppressive agent is:
a) prednisone;
b) azathioprine; or
c) cyclosporin.
5. The method of claim 1 , wherein the individual exhibits signs of impaired glucose homeostasis.
6. The method of claim 5 , wherein impaired glucose homeostasis is measured by plasma glucose levels either during fasting or after a glucose load.
7. The method of claim 6 , wherein the plasma glucose levels are:
a) between 110 to 126 mg per dL during fasting; or
b) between 140 and 200 mg per dL after a glucose load.
8. The method of claim 5 , wherein at least one of the anti-IL-23p19 or anti-IL-23R antibodies, or antigen binding fragments thereof, or the anti-IL-17 antibody, or antigen binding fragment thereof, is a monoclonal antibody, or antigen binding fragment thereof.
9. The method of claim 8 , further comprising administering an immunosuppressive agent.
10. The method of claim 9 , wherein the immunosuppressive agent is:
a) prednisone;
b) azathioprine; or
c) cyclosporin.
11. The method of claim 1 , wherein at least one of the anti-IL-23p19 or anti-IL-23R antibodies, or antigen binding fragments thereof, or the anti-IL-17 antibody, or antigen binding fragment thereof, is a humanized antibody, or antigen binding fragment thereof.
12. The method of claim 1 , wherein at least one of the anti-IL-23p19 or anti-IL-23R antibodies, or antigen binding fragments thereof, or the anti-IL-17 antibody, or antigen binding fragment thereof, is an Fab, Fv, or F(ab′) 2 fragment.
13. The method of claim 1 , wherein at least one of the anti-IL-23p19 or anti-IL-23R antibodies, or antigen binding fragments thereof, or the anti-IL-17 antibody, or antigen binding fragment thereof, is a single chain antibody.
14. The method of claim 1 , wherein an anti-IL-23p19 antagonist antibody, or antigen binding fragment thereof, is administered in step (a).
15. The method of claim 1 , wherein an anti-IL-23R antagonist antibody, or antigen binding fragment thereof, is administered in step (a).
16. The method of claim 5 , wherein at least one of the anti-IL-23p19 or anti-IL-23R antibodies, or antigen binding fragments thereof, or the anti-IL-17 antibody, or antigen binding fragment thereof, is a humanized antibody, or antigen binding fragment thereof.
17. The method of claim 5 , wherein at least one of the anti-IL-23p19 or anti-IL-23R antibodies, or antigen binding fragments thereof, or the anti-IL-17 antibody, or antigen binding fragment thereof, is an Fab, Fv, or F(ab′) 2 fragment.
18. The method of claim 5 , wherein at least one of the anti-IL-23p19 or anti-IL-23R antibodies, or antigen binding fragments thereof, or the anti-IL-17 antibody, or antigen binding fragment thereof, is a single chain antibody.
19. The method of claim 1 , wherein the individual exhibits signs of impaired glucose homeostasis, and an anti-IL-23p19 antagonist antibody, or antigen binding fragment thereof, is administered in step (a).
20. The method of claim 1 , wherein the individual exhibits signs of impaired glucose homeostasis, and an anti-IL-23R antagonist antibody, or antigen binding fragment thereof, is administered in step (a).